SCYNEXIS, Inc. Announces Positive Results in its Proof-of-Concept Phase 2 Study of SCY-078, the First Member of a Novel Class of Glucan Synthase Inhibitors
June 08, 2016 16:05 ET
|
SCYNEXIS, Inc.
Confirmation of Clinically Relevant Antifungal Activity of SCY-078 in Patients with Candida Infections Company to Host a Conference Call Today at 5:00pm ET to Discuss Results JERSEY CITY, N.J.,...
SCYNEXIS, Inc. Receives Orphan Drug Designation for SCY-078 for the Treatment of Invasive Candida Infections
May 13, 2016 08:00 ET
|
SCYNEXIS, Inc.
JERSEY CITY, N.J., May 13, 2016 (GLOBE NEWSWIRE) -- Drug development company SCYNEXIS, Inc. (Nasdaq:SCYX) today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug...
SCYNEXIS, Inc. Reports First Quarter 2016 Financial Results and Provides Company Update
May 09, 2016 09:25 ET
|
SCYNEXIS, Inc.
JERSEY CITY, N.J., May 09, 2016 (GLOBE NEWSWIRE) -- Drug development company SCYNEXIS, Inc. (Nasdaq:SCYX) today reported financial results for the quarter ended March 31, 2016, and provided an...
SCYNEXIS Receives Designation as a Small and Medium Enterprise by the European Medicines Agency
April 19, 2016 09:15 ET
|
SCYNEXIS, Inc.
JERSEY CITY, N.J., April 19, 2016 (GLOBE NEWSWIRE) -- Drug development company SCYNEXIS, Inc. (Nasdaq:SCYX) announced today that the Company has been granted Small and Medium Sized Enterprise...
SCYNEXIS Presents Data Supporting the Activity of its Lead Antifungal Drug Candidate SCY-078 Against Antifungal-resistant Candida Strains at the 13th ASM Conference on Candida and Candidiasis
April 15, 2016 09:00 ET
|
SCYNEXIS, Inc.
JERSEY CITY, N.J., April 15, 2016 (GLOBE NEWSWIRE) -- Drug development company SCYNEXIS, Inc. (Nasdaq:SCYX) announced today that results of three nonclinical studies of the company’s lead clinical...
SCYNEXIS, Inc. to Present at the 15th Annual Needham Healthcare Conference
April 06, 2016 16:30 ET
|
SCYNEXIS, Inc.
JERSEY CITY, N.J., April 06, 2016 (GLOBE NEWSWIRE) -- Drug development company SCYNEXIS, Inc. (NASDAQ:SCYX) today announced that the Company will present at the 15th Annual Needham Healthcare...
SCYNEXIS to Present Data from Lead Antifungal Drug Candidate SCY-078 at 13th ASM Conference on Candida and Candidiasis
April 06, 2016 09:20 ET
|
SCYNEXIS, Inc.
JERSEY CITY, N.J., April 06, 2016 (GLOBE NEWSWIRE) -- Drug development company SCYNEXIS, Inc. (Nasdaq:SCYX) announced today that results of three nonclinical studies of the company’s lead clinical...
SCYNEXIS, Inc. Reports Full Year 2015 Financial Results and Provides Company Update
March 07, 2016 08:36 ET
|
SCYNEXIS, Inc.
JERSEY CITY, N.J., March 07, 2016 (GLOBE NEWSWIRE) -- Drug development company SCYNEXIS, Inc. (Nasdaq:SCYX) today reported financial results for the year ended December 31, 2015, and provided an...
SCYNEXIS, Inc. to Present at the Cowen and Company 36th Annual Health Care Conference
February 29, 2016 17:30 ET
|
SCYNEXIS, Inc.
JERSEY CITY, N.J., Feb. 29, 2016 (GLOBE NEWSWIRE) -- Drug development company SCYNEXIS, Inc. (NASDAQ:SCYX) today announced that the Company will present at the Cowen and Company 36th Annual Health...
SCYNEXIS, Inc. to Present at Upcoming Investor Conferences
February 03, 2016 09:05 ET
|
SCYNEXIS, Inc.
JERSEY CITY, N.J., Feb. 03, 2016 (GLOBE NEWSWIRE) -- Drug development company SCYNEXIS, Inc. (NASDAQ:SCYX) today announced that the Company will present at the following upcoming investor...